key: cord-0918242-tscvpqf5 authors: Shi, Ke; Liu, Yao; Zhang, Qun; Ran, Chong-ping; Hou, Jie; Zhang, Yi; Wang, Xian-bo title: Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment date: 2021-12-28 journal: Chin J Integr Med DOI: 10.1007/s11655-021-3313-x sha: 3441873e0f401e5eae1c113def18696137192f68 doc_id: 918242 cord_uid: tscvpqf5 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is a major public health issue. The epidemic is unlikely to be contained until the global launch of safe and effective vaccines that could prevent serious illnesses and provide herd immunity. Although most patients have mild flu-like symptoms, some develop severe illnesses accompanied by multiple organ dysfunction. The identification of pathophysiology and early warning biomarkers of a severe type of COVID-19 contribute to the treatment and prevention of serious complications. Here, we review the pathophysiology, early warning indicators, and effective treatment of Chinese and Western Medicine for patients with a severe type of COVID-19. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material (Appendix 1) is available in the online version of this article at DOI: 10.1007/s11655-021-3313-x. • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • Notes: ACE2: angiotensin-converting enzyme 2; Ang: angiotensin; ADAM-17: a disintegrin and metalloproteinase 17; AT1R: angiotensin 1 receptors; COVID-19: coronavirus disease 2019; CXCL: CXC-chemokine ligand; CCL: chemokine ligand; IL: interleukin; ICAM: intercellular adhesion molecule; HIF: hypoxia-inducible factor; MCP: monocyte chemoattractant protein; NETs: neutrophil extracellular traps; PSGL1: P-selectin glycoprotein ligand 1; PAR1: proteinase activated receptor 1; RAAS: renin-angiotensin-aldosterone system; ROS: reactive oxygen species; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2; TMPRSS2: transmembrane protease serine 2; TLR: toll-like receptor; TNF-α: tumor necrosis factoralpha; TF: tissue factor; vWF: von Willebrand factor multimers the late stage of disease, SARS-CoV-2 is mainly replicated in the lower respiratory tract, accompanied by ARDS in severe cases. (17, 18) Numerous studies have indicated that SARS-CoV-2 is located in endothelial cells (ECs) in sections of the lungs, kidneys, and intestine. (12, 19) Endotheliopathy and Thrombosis The key points of thrombosis are endothelial dysfunction, complement activation, immune response initiation, cytokine infiltration, platelet-leukocyte aggregation, hypoxia, and thrombin generation. (20, 21) Indeed, complement is an important component of innate immunity to SARS-CoV-2. (20) The recognition of the virus by toll-like receptor 7 (TLR7) may lead to innate immune hyperactivation. (22) Unrestrained activation of the complement increases endothelial permeability, facilitates the recruitment of monocytes and neutrophils, and mediates generalized microvascular injury, which culminates in immunothrombosis in severe COVID-19 cases. (23, 24) The activation of platelets releases chemokines, including CXC-chemokine ligand 1 (CXCL1), CXCL5, chemokine ligand 3 (CCL3), and CCL5, (25) which facilitate Notes: Pathophysiological characteristics of lung: endothelial injury, inflammation, and thrombosis. Other organ dysfunction, including heart, brain, kidney, liver, and deep vein, are also summarized. IL: interleukin; TNF-α: tumor necrosis factor-alpha; IFNγ: interferon gamma; MCP: monocyte chemoattractant protein; G-CSF: granulocyte-colony stimulating factor; MIP: macrophage infl ammatory protein; IP10: IFNγ-inducible protein 10; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2; Type Ⅱ P: type Ⅱ pneumocyte; ACE2: angiotensin-converting enzyme 2 leukocyte recruitment to sites of vascular injury. (26) Activated platelets promote neutrophils to discharge eneutrophil extracellular traps (NETs). (27, 28) Although NETs are beneficial inensnaring pathogens, excessive NETs correlate with proinfl ammatory cytokine production, activation of the coagulation pathway, and multiple organ damage and death. (29) Platelet degranulation, leukocyteplatelet interactions, and platelet C3 release in turn stimulate NETs. (30, 31) Patients with severe type of COVID-19 have been demonstrated to have increased interleukin (IL)-1β, IL-6, monocyte chemoattractant protein-1 (MCP-1), interferon gamma (IFNγ), IFNγ-inducible protein 10 (IP10), macrophage infl ammatory protein 1α (MIP-1α), and tumor necrosis factor (TNF)-α. (32) (33) (34) These infl ammatory cytokines facilitate vascular endotheliopathy, leading to the release of von Willebrand factor and overexpression of tissue factor (TF) and fibrinogen. (35) (36) (37) These factors contribute substantially to increased mortality due to COVID-19 and affect other organs, leading to ischemic stroke, pulmonary embolisms, cardiac injury, acute kidney injury, and deep vein thrombosis (DVT). (18, 20, (37) (38) (39) (40) Infl ammation-induced endothelial injury can lead to abundant plasminogen activator infi ltration. (23, 41) Thrombin, via proteinase activated receptor 1, promotes platelet activation, enhances the release of infl ammatory factors, and activates the coagulation pathway. (42) In addition, hypoxia induces upregulation of hypoxia-inducible factor 1 signaling pathway, contributing to TF expression, vasoconstriction, infl ammation, and thrombosis. (43, 44) Immune Infl ammatory Response Overactivation of innate immunity-induced cytokine storm is a feature of severe COVID-19. (45) Activated macrophages and neutrophils play a prominent role in the hyperinflammatory response and release cytokines and chemokines, including IL-1β, IL-6, IL-7, granulocyte-colony stimulating factor (G-CSF), IFN-γ, MCP-1, MIP-1α, IP10, TNF-α, and C-reactive protein (CRP). (2, (45) (46) (47) (48) Furthermore, a prominent feature of severe SARS-CoV-2 infection is lymphocytopenia, which is associated with adverse outcomes. (49, 50) Because of massive T-cell lymphodepletion and dysregulation of the immune response, a number of cytokines are released. Excessive IL-6 can induce TF expression on mononuclear cells, upregulation of adhesion molecules including P-and E-selectin and integrin α and β3, and subsequently act to enhance coagulation and thrombin generation. (51, 52) Disorders of RAAS Dysregulation of the RAAS is involved in the pathophysiological mechanism of severe COVID-19a s s o c i a t e d t i s s u e d a m a g e . ( 5 3 ) A C E 2 s e r v e s a counterbalancing role in the RAAS, including bloodpressure regulation, fibrosis, and inflammation. (54, 55) ACE promotes the conversion of angiotensin Ⅰ (Ang Ⅰ) to Ang Ⅱ. (56) SARS-CoV-2 impairs the activity of ACE2, resulting in an increase in Ang Ⅱ with increased angiotensin 1 receptor (AT1R) activation. (55, (57) (58) (59) Subsequently, the activation of a disintegrin and metalloproteinase 17 resulted in ACE2 membrane shedding, RAAS overactivation, and a proinflammatory cascade. (60) Additionally, downregulation of ACE2 expression by SARS-CoV-2 infection reduced ACE2 and activated kallikrein-bradykinin pathway, increasing risk of vascular leakage, leading to further pulmonary edema. (41) Abnormal activation of ACE/Ang Ⅱ axis leads to pulmonary vasoconstriction, inflammation, fibrosis, hypertrophy, and accumulation of reactive oxygen species. (12, 58) Pathogenesis of CM COVID-19 belongs to the category of "plague" in CM theory, which is caused by the cold-dampness epidemic virus. (61, 62) This disease is located in Fei (Lung) and can affect Xin (Heart), Pi (Spleen), Gan (Liver), Shen (Kidney), and other organs. (62, 63) The basic pathogenesis is characterized by dampness, toxin, blood stasis, and closure. (64) Compared to patients with non-severe COVID-19, those with severe COVID-19 were older, male, and had more comorbidities. (65) (66) (67) (68) Regarding the underlying diseases associated with severe disease, the most recorded one was hypertension, followed by diabetes mellitus, cardiac diseases, kidney disease, chronic obstructive pulmonary disease (COPD), and malignant tumors (69) (70) (71) (72) Downregulated PaO 2 :FiO 2 and SpO 2 /FiO 2 , and upregulated sepsis-related organ failure assessment are risk factors for death. (32, 33, 70) Hematologic Biomarkers The higher the white blood cell (WBC), neutrophil count, neutrophil-lymphocyte ratio (NLR), and basophils, and the lower the platelet, lymphocyte (especially CD4 + and CD8 + T cells), and monocyte count, the higher the mortality. (73) Biochemical Biomarkers Patients with severe illness more frequently showed increased alanine aminotransferase, aspartate aminotransferase, ferritin, and lactate dehydrogenase l e v e l s a n d l o w e r l e v e l s o f a l b u m i n . (74) L a c t a t e dehydrogenase (LDH), direct bilirubin, creatine kinase, urea, and calcium may serve as clinical predictors of severe or critical illness. (66, 75, 76) Independent risk factors associated with mortality included hypercholesterolemia, liver dysfunction, kidney dysfunction, increased lactate dehydrogenase and ferritin, and low albumin levels. (77) Coagulation Biomarkers Patients with severe type of COVID-19 had higher D-dimer, fibrin degradation products, and prothrombin time than those with non-severe disease. Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization, critical illness, and death. (78) Immune and Infl ammatory Biomarkers The inflammatory factors, mainly IL-6, increase substantially, which results indisease progression approximately 7-14 days after onset. (79) CRP is related to disease progression and is a clinical predictor of severity and mortality. (80) Other relevated infl ammatory biomarkers include procalcitonin, serum amyloid protein A, TNF-α, IL-7, IL-9, IL-10, IL-6: alpha-1 antitrypsin ratio, monokineinduced IFN-γ, granulocyte-colony stimulating factor, IP10, MCP-1, MCP-3, and MIP-1α. (66, (81) (82) (83) (84) (85) Patients with severe disease had a lower natural killer cell count, IFN-γ, and type-Ⅰ IFNs than those with non-severe COVID-19. (86, 87) Other New Biomarkers Markers of cardiac and muscle injury were elevated in patients with both severe and fatal COVID-19. Initial cardiac troponin Ⅰ, hepatocyte growth factor, alpha-1antichymotrypsin, vascular endothelial growth factor-D, and serum amyloid P-component were substantially higher in patients with critical illness. (84, 88) Notes: The text colors correspond to warning indicators for disease severity. Green text: severe illness; purple text: severe or critical illness; blue text: mortality; black text: possible predictive factors for severe, critical illness, and mortality. SOFA: sepsis-related organ failure assessment; PaO 2 : partial pressure of oxygen; FiO 2 : fraction of inspired O 2 ; SpO 2 : pulse oxygen saturation; NLR: netrophillymphocty ratio; CRP: C-reactive protein; PCT: procalcitonin; SAA: serum amyloid protein A; IL: interleukin; TNF-α: tumor necrosis factor-α; AAT: alpha-1 antitrypsin; IFN: interferon; G-SCF: granulocyte colony-stimulating factor; IP10: IFN-γ-induced protein 10; MCP: monocyte chemotactic protein; MIP1α: macrophage infl ammatory protein 1α; NK cells: natural killer cells Remdesivir, a nucleoside analog prodrug that impedes viral RNA synthesis, has been routinely used in the treatment of viral infections. (89, 90) In a randomized study conducted by Wang, et al, (91) researchers found no statistically significant benefit of remdesivir when comparing placebo group with remdesivir group. Although not statistical significance was found, patients receiving remdesivir showed reduced duration of clinical symptoms compared to the control group within 10 days of symptom duration. Of note, a study by Siemieniuk, et al (92) verifi ed the effectiveness of remdesivir in shortening both the time to recovery and the duration of mechanical ventilation; however, the mortality benefit is uncertain. In view of the clinical effectiveness of remdesivir, the United States Food and Drug Administration (FDA) has authorized remdesivir for emergency use in the treatment of patients with severe disease. (93) Moreover, the drug has been recommended by the European Union. (94) Corticosteroids The National Institutes of Health COVID-19 Treatment Panel Guidelines recommended dexamethasone at a dose of 6 mg once daily for up to 10 days for patients on mechanical ventilation and oxygen. (95) Available evidence suggests that corticosteroids have been identified as the only drugs that reduce mortality and mechanical ventilation compared to standard treatment. (96) A trial from the United Kingdom found that lowdose dexamethasone was associated with a 33% lower mortality rate in patients receiving invasive ventilation and 20% in those needing oxygen compared to the usual care group. (97) In a multicenter study in hospitalized patients with ARDS patients administered dexamethasone had a 60-day mortality rate that was 15% lower than that of the control group. (98) A cohort study from China showed that methylprednisolone may reduce the mortality rate and has a signifi cant clinical benefi t in patients with COVID-19 with ARDS. (33) Thus, the appropriate dosage of corticosteroids may maximize benefi ts and minimizing adverse effects. Given that thrombotic complications confer a high death rate in patients with COVID-19, prophylactic or therapeutic anticoagulation (AC) is of critical importance and established in advance. (99) Unfractionated heparin (UFH) or lowmolecular-weight heparin (LMWH) in hospitalized patients should be administered unless they have contraindications (active bleeding or severe thrombocytopenia). (100) (101) (102) A retrospective analysis by Tang, et al (103) found that patients administered heparin had a reduction in 28-day mortality. The use of AC mainly with LMWH markedly decreased the 28-day mortality in patients with severe COVID-19 with a sepsis-induced coagulopathy score of 4 points or substantially increased D-dimer. Nevertheless, even with the use of LMWH or UFH, thrombotic events still occur. (7) In a multicenter study, many patients with ARDS still experienced thrombotic events despite AC treatment, in which D-dimer and fi brinogen levels increased markedly. (104) Thus, AC treatment needs to take into account the dose and coagulation characteristics of patients. Convalescent plasma (CP) therapy has been applied in the treatment of SARS, Middle East Respiratory Syndrome, and H1N1 influenza, and has demonstrated efficacy. (105) (106) (107) Shen, et al (108) reported that 5 patients with COVID-19 with ARDS were successfully treated with CP, as evidenced by can improve the curative rate, shorten the average hospital stay, and reduce the number of cases from mild to severe. (112) (113) (114) A propensity score-based analysis suggested that CM is effective in reducing the mortality rate in severe and critical illnesses. (115) CM combined with conventional treatment has a protective effect on patients with severe COVID-19, and can reduce fever time and mortality. (116) A meta-analysis demonstrated that CM can effectively reduce severe cases, improve lung imaging manifestations, and shorten the length of hospital stay. (1) Qingfei Compared with the control group, the average course of fever and pulmonary exudative lesions in the YDJDG group was remarkably shorter. (121) Among the "Three CM and three formulas" CM, with multi-targets and multi-pathways, has potential advantages in human body regulation. We analyzed the mechanism of CM in the treatment of severe type of COVID-19: (1) Direct inhibition of viruses. Emerging evidence suggested that CM rich in flavonoid compounds has an antiviral effect. (123) Radix Scutellariae and Radix Glycyrrhizae in MXSG exhibit potential antiviral effects by binding to ACE2 and 3CL hydrolase. (124) (2) Inhibition of inflammatory storm and regulation immune function. RDN possesses the effect of regulating the activation of IL-6, IL-8, and TNF-α, which protects COVID-19 patients from lung injury. (125) XBJ plays a prominent role in anti-inflammation and has good immunostimulatory activity. (126) (3) Inhibition of thrombosis. Some studies have shown that MXSG exerts the effect in increasing the solubility of ephedrine, which can inhibit platelet adhesion and aggregation in Ephedra. (124, 127) (4) Inhibition of oxidative stress. Emerging evidence indicated that glycyrrhizic acid has a good effect on anti-oxidative stress, inhibition of infl ammatory reaction, and immunoregulation. (128) Owing to direct viral injury, endothelial damage and thrombosis, immune dysregulation, and RAAS overactivation, patients with severe COVID-19 might experience multiple organ complications or even die. Therefore, early identification is crucial to decrease the severity of disease and mortality of patients. The The authors declare that they have no confl icts of interest. Wang XB was responsible for the design of this paper. Shi K and Liu Y drafted the manuscript and contributed equally to this work. Zhang Q, Ran CP, Hou J, and Zhang Y were responsible for collecting information. Wang XB revised and commented on the manuscript. All authors read and approved the fi nal version for publication. Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta-analysis Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment COVID-19 vaccine development and a potential nanomaterial path forward Extrapulmonary manifestations of COVID-19 Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19 Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 Virological assessment of hospitalized patients with COVID-2019 COVID-19: the vasculature unleashed Blood vessel injury may spur disease's fatal second phase The case of complement activation in COVID-19 multiorgan impact The emerging threat of (Micro) thrombosis in COVID-19 and its therapeutic implications Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes Cross talk pathways between coagulation and infl ammation Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of fi ve cases Thrombosis as an intravascular effector of innate immunity The role of platelets in mediating a response to human influenza infection Targeting potential drivers of COVID-19: neutrophil extracellular traps Endocarditis pathogen promotes vegetation formation by inducing intravascular neutrophil extracellular traps through activated platelets The cytokine storm and COVID-19 Circulating platelets as mediators of immunity, infl ammation, and thrombosis Platelets and infection-an emerging role of platelets in viral infection Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection The use of anti-infl ammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin • 10 • Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 COVID-19 and cardiovascular disease Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Evolving functions of endothelial cells in infl ammation COVID-19 cytokine storm: the interplay between infl ammation and coagulation The stimulation of thrombosis by hypoxia The endothelium in hypoxic pulmonary vasoconstriction COVID-19: consider cytokine storm syndromes and immunosuppression Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study Adaptive immune cells temper initial innate responses Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106) Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo Is there an association between COVID-19 mortality and the renin-angiotensin system? a call for epidemiologic investigations Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review Advances in understanding the renin-angiotensinaldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy Dual pathway for angiotensin Ⅱ formation in human internal mammary arteries Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target The pivotal link between ACE2 defi ciency and SARS-CoV-2 infection Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th Anniversary of the discovery of ACE2 Angiotensin Ⅱ induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ ADAM-17: a positive feedback mechanism in the RAS Understanding and thinking of novel coronavirus pneumonia in traditional Chinese medicine Discussion on traditional Chinese medicine prevention and treatment strategies of Coronavirus Disease 2019 (COVID-19) from the perspective of "cold-dampness pestilence Clinical features, and syndrome differentiation of novel coronavirus pneumonia in traditional Chinese medicine Thinking on etiology and pathogenesis of novel coronavirus pneumonia in traditional Chinese medicine COVID-19 with different severities: a multicenter study of clinical features Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Clinical characteristics and outcomes in patients with Coronavirus Disease 2019 and multiple sclerosis Determinants of COVID-19 disease severity in patients with cancer Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study Factors associated with death in critically ill patients with Coronavirus Disease 2019 in the US The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study Clinical and immunological features of severe and moderate coronavirus disease 2019 Early triage of critically ill COVID-19 patients using deep learning Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19 COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study Characterization of the inflammatory response to severe COVID-19 illness Viral and host factors related to the clinical outcome of COVID-19 Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 Proteomic and metabolomic characterization of COVID-19 patient sera Immunological and infl ammatory profiles in mild and severe cases of COVID-19 Impaired type Ⅰ interferon activity and infl ammatory responses in severe COVID-19 patients VEGF-D: a novel biomarker for detection of COVID-19 progression Compassionate use of remdesivir for patients with severe Covid-19 Arguments in favour of remdesivir for treating SARS-CoV-2 infections Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Drug treatments for Covid-19: living systematic review and network meta-analysis FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy Covid-19: remdesivir is recommended for authorisation by European Medicines Agency COVID-19 and dexamethasone: a potential strategy to avoid steroid-related strongyloides hyperinfection Covid-19: low dose steroid cuts death in ventilated patients by one third, trial fi nds Dexamethasone in hospitalized patients with Covid-19 Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients Coagulopathy in COVID-19: focus on vascular thrombotic events Coagulation abnormalities and thrombosis in patients with COVID-19 COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Use of convalescent plasma therapy in SARS patients in Hong Kong Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Covid-19: FDA approves use of convalescent plasma to treat critically ill patients Refl ections on treatment of COVID-19 with traditional Chinese medicine The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection Exploring an integrative therapy for treating COVID-19: a randomized controlled trial Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective cohort study Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): in silico and experimental study Traditional Chinese herbal medicine at the forefront battle against COVID-19: clinical experience and scientifi c basis Association between early treatment with Qingfei Paidu Decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: a retrospective case series study at early stage of the COVID-19 epidemic in Wuhan Yindan Jiedu Granules, a traditional Chinese medicinal formulation, as a potential treatment for coronavirus disease 2019 Xuebijing Injection in the treatment of COVID-19: a retrospective case-control study Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Identifying potential treatments of COVID-19 from traditional Chinese medicine (TCM) by using a datadriven approach Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verifi cation Discovery of Xuebijing Injection exhibiting protective effi cacy on sepsis by inhibiting the expression of HMGB1 in septic rat model designed by cecal ligation and puncture Hemostatic effects of ephedrine Natural products in licorice for the therapy of liver diseases: progress and future opportunities The authors are grateful to ZHAO Ting for her constructive comments in improving the language, grammar, and readability of the paper.